Lars Bruening appointed vice-chair of EMG
The EMG works to promote a greater understanding of the value of member companies and the research, development and manufacture of the medicines they produce and the benefits to the NHS and the UK economy.
Lars said: “I’m very much looking forward to be working with and representing the EMG companies to shape the healthcare environment – helping to improve and accelerate the benefits which patients derive from innovation.”
EMG members include some of the biggest pharmaceutical companies in the world as well as medium-sized and small, specialised companies, and new biopharmaceutical companies, bringing innovative new medicines to UK patients. The organisation invests more than £1 billion per year in research and development in the UK.